

# Ricard Cervera i Segura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/519398/publications.pdf>

Version: 2024-02-01

318  
papers

28,119  
citations

9756

73  
h-index

6113

159  
g-index

341  
all docs

341  
docs citations

341  
times ranked

15154  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. <i>Arthritis and Rheumatism</i> , 2002, 46, 1019-1027.	6.7	1,736
2	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3918-3930.	6.7	1,277
3	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
4	Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period. <i>Medicine (United States)</i> , 1999, 78, 1071-1077.	0.4	1,107
5	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
6	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.5	868
7	Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. <i>Arthritis and Rheumatism</i> , 2002, 46, 2121-2131.	6.7	849
8	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
9	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.5	664
10	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.5	558
11	Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. <i>American Journal of Medicine</i> , 1994, 96, 3-9.	0.6	484
12	Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients. <i>Medicine (United States)</i> , 1998, 77, 195-207.	0.4	478
13	International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 17-23.	0.5	471
14	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , 2006, 8, 209.	1.6	469
15	Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2083-2089.	0.5	424
16	Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients. <i>Medicine (United States)</i> , 1999, 78, 167-175.	0.4	367
17	Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1343-1349.	0.5	343
18	Catastrophic Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 2001, 80, 355-377.	0.4	342

#	ARTICLE	IF	CITATIONS
19	Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 3934-3940.	6.7	325
20	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
21	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the "CAPS Registry". <i>Journal of Autoimmunity</i> , 2009, 32, 240-245.	3.0	307
22	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. <i>Arthritis and Rheumatism</i> , 2006, 54, 2568-2576.	6.7	294
23	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
24	Diagnosis and classification of the antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2014, 48-49, 20-25.	3.0	238
25	Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 456-459.	0.5	236
26	Chorea in the Antiphospholipid Syndrome: Clinical, Radiologic, and Immunologic Characteristics of 50 Patients from Our Clinics and the Recent Literature. <i>Medicine (United States)</i> , 1997, 76, 203-226.	0.4	235
27	Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 1305-1313.	2.9	224
28	Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. <i>Autoimmunity Reviews</i> , 2013, 12, 1085-1090.	2.5	211
29	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. <i>Autoimmunity Reviews</i> , 2016, 15, 1120-1124.	2.5	211
30	Antiphospholipid syndrome. <i>Thrombosis Research</i> , 2017, 151, S43-S47.	0.8	195
31	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. <i>Pediatrics</i> , 2008, 122, e1100-e1107.	1.0	193
32	Adrenal Involvement in the Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 2003, 82, 106-118.	0.4	175
33	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.	2.5	166
34	Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. <i>American Journal of Medicine</i> , 2002, 112, 37-43.	0.6	163
35	Etiopathogenesis of Behcet's disease. <i>Autoimmunity Reviews</i> , 2010, 9, 241-245.	2.5	161
36	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 526-531.	0.5	157

#	ARTICLE	IF	CITATIONS
37	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Lupus Science and Medicine</i> , 2015, 2, e000123-e000123.	1.1	155
38	Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms. <i>Autoimmunity Reviews</i> , 2010, 10, 74-79.	2.5	152
39	Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials. <i>Arthritis and Rheumatism</i> , 2013, 65, 2143-2153.	6.7	152
40	The antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2017, 76, 10-20.	3.0	146
41	The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2018, 92, 1-11.	3.0	143
42	Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 217-230.	1.6	142
43	High Prevalence of Significant Heart Valve Lesions in Patients with the 'Primary' Antiphospholipid Syndrome. <i>Lupus</i> , 1991, 1, 43-47.	0.8	132
44	Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. <i>Rheumatology</i> , 2005, 44, 756-761.	0.9	131
45	Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 838-844.	0.5	123
46	Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 322-332.	1.6	122
47	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. <i>Autoimmunity Reviews</i> , 2015, 14, 387-395.	2.5	121
48	Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the 'Euro-Lupus Project'. <i>Autoimmunity Reviews</i> , 2006, 5, 180-186.	2.5	115
49	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>TJ ETQq1 1 0.784314 rgBT /Overlock</i>	2.5	107
50	Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. <i>Arthritis and Rheumatism</i> , 1998, 41, 1420-1427.	6.7	106
51	Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. <i>Autoimmunity Reviews</i> , 2015, 14, 153-159.	2.5	106
52	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019, 18, 406-414.	2.5	106
53	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
54	'Primary', 'Secondary' and Other Variants of the Antiphospholipid Syndrome. <i>Lupus</i> , 1994, 3, 293-298.	0.8	100

#	ARTICLE	IF	CITATIONS
55	The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. <i>Clinical Rheumatology</i> , 2018, 37, 483-493.	1.0	99
56	Hepatitis C virus infection mimicking systemic lupus erythematosus: Study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 43, 2801-2806.	6.7	98
57	The. <i>Rare Diseases of the Immune System</i> , 2015, , 249-262.	0.1	98
58	Transverse Myelitis Affecting More Than 4 Spinal Segments Associated with Systemic Lupus Erythematosus: Clinical, Immunological, and Radiological Characteristics of 22 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 246-256.	1.6	97
59	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
60	Budd-Chiari Syndrome Secondary to Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 2001, 80, 345-354.	0.4	95
61	Current treatment of antiphospholipid syndrome: lights and shadows. <i>Nature Reviews Rheumatology</i> , 2015, 11, 586-596.	3.5	93
62	Bidirectional effects on autoimmunity and reproduction. <i>Human Reproduction Update</i> , 2008, 14, 359-366.	5.2	92
63	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 740-746.	0.5	89
64	Systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 841-855.	1.4	89
65	Pediatric catastrophic antiphospholipid syndrome: Descriptive analysis of 45 patients from the 'CAPS Registry'. <i>Autoimmunity Reviews</i> , 2014, 13, 157-162.	2.5	88
66	Adalimumab for the treatment of Behcet's disease: experience in 19 patients. <i>Rheumatology</i> , 2012, 51, 1825-1831.	0.9	87
67	Update on the Diagnosis, Treatment, and Prognosis of the Catastrophic Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2010, 12, 70-76.	2.1	86
68	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. <i>Autoimmunity Reviews</i> , 2006, 6, 72-75.	2.5	83
69	Hepatitis C virus infection in 'primary' Sjogren's syndrome: prevalence and clinical significance in a series of 90 patients. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 173-175.	0.5	82
70	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	2.9	81
71	Moving towards a molecular taxonomy of autoimmune rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2018, 14, 75-93.	3.5	80
72	Update on the Catastrophic Antiphospholipid Syndrome and the 'CAPS Registry'. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 333-338.	1.5	79

#	ARTICLE	IF	CITATIONS
73	Neuropsychiatric systemic lupus erythematosus: Magnetic resonance imaging findings and correlation with clinical and immunological features. <i>Autoimmunity Reviews</i> , 2013, 12, 1166-1170.	2.5	77
74	Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases. <i>Autoimmunity Reviews</i> , 2018, 17, 703-708.	2.5	76
75	Management of refractory cases of catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2011, 10, 664-668.	2.5	75
76	Clinical Features Related to Antiphospholipid Syndrome in Patients with Chronic Viral Infections (Hepatitis C Virus/HIV Infection): Description of 82 Cases. <i>Clinical Infectious Diseases</i> , 2004, 38, 1009-1016.	2.9	74
77	Microvascular and microangiopathic antiphospholipid-associated syndromes (â€œMAPSâ€). <i>Autoimmunity Reviews</i> , 2008, 7, 164-167.	2.5	74
78	Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: A prospective, long-term, followup study. <i>Arthritis and Rheumatism</i> , 2005, 53, 460-467.	6.7	72
79	Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant). <i>Current Rheumatology Reports</i> , 2018, 20, 62.	2.1	72
80	Class III-IV Proliferative Lupus Nephritis and Pregnancy: A Study of 42 Cases. <i>American Journal of Reproductive Immunology</i> , 2005, 53, 182-188.	1.2	71
81	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	2.5	71
82	Patterns of systemic lupus erythematosus expression in Europe. <i>Autoimmunity Reviews</i> , 2014, 13, 621-629.	2.5	71
83	Antiphospholipid syndrome: pathogenic mechanisms. <i>Autoimmunity Reviews</i> , 2003, 2, 86-93.	2.5	70
84	The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. <i>Rheumatology</i> , 2018, 57, 1264-1270.	0.9	70
85	The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2000, 43, 2349-2358.	6.7	69
86	The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. <i>International Immunology</i> , 2007, 19, 857-865.	1.8	69
87	Annual direct medical cost of active systemic lupus erythematosus in five European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 154-160.	0.5	68
88	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	1.8	66
89	Prevalence of hepatitis C serum antibody in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2009, 32, 261-266.	3.0	65
90	Diagnosis and classification of Susac syndrome. <i>Autoimmunity Reviews</i> , 2014, 13, 347-350.	2.5	65

#	ARTICLE	IF	CITATIONS
91	The Multiple Autoimmune Syndromes. A Clue for the Autoimmune Tautology. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 256-264.	2.9	64
92	Unusual Manifestations of the Antiphospholipid Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2003, 25, 61-78.	2.9	63
93	Intestinal Involvement Secondary to the Antiphospholipid Syndrome (APS): Clinical and Immunologic Characteristics of 97 Patients: Comparison of Classic and Catastrophic APS1. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 36, 287-296.	1.6	63
94	Relapsing Catastrophic Antiphospholipid Syndrome: Report of Three Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 366-372.	1.6	62
95	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. <i>Autoimmunity Reviews</i> , 2016, 15, 9-15.	2.5	62
96	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	2.5	62
97	Factors influencing polyautoimmunity in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2010, 9, 229-232.	2.5	60
98	Epidemiology and management of refractory lupus nephritis. <i>Autoimmunity Reviews</i> , 2011, 10, 655-663.	2.5	60
99	Does seronegative antiphospholipid syndrome really exist?. <i>Autoimmunity Reviews</i> , 2012, 11, 581-584.	2.5	60
100	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	1.5	60
101	Morbidity and Mortality in the Catastrophic Antiphospholipid Syndrome: Pathophysiology, Causes of Death, and Prognostic Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 290-294.	1.5	58
102	Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature. <i>Autoimmunity Reviews</i> , 2011, 10, 679-684.	2.5	58
103	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2071-2074.	0.5	58
104	Risk factors of vertebral fractures in women with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2009, 28, 579-585.	1.0	57
105	Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a caseâ€“control study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 61-66.	0.5	55
106	Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. <i>Arthritis Research and Therapy</i> , 2013, 15, R41.	1.6	55
107	Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. <i>Nature Reviews Rheumatology</i> , 2010, 6, 296-300.	3.5	54
108	Catastrophic Antiphospholipid Syndrome. <i>Journal of Clinical Rheumatology</i> , 2002, 8, 157-165.	0.5	53

#	ARTICLE	IF	CITATIONS
109	Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. <i>Autoimmunity Reviews</i> , 2006, 6, 48-53.	2.5	53
110	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020, 59, 1306-1314.	0.9	53
111	Pregnancy outcome in systemic lupus erythematosus: good news for the new millennium. <i>Autoimmunity Reviews</i> , 2002, 1, 354-359.	2.5	52
112	Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. <i>Autoimmunity Reviews</i> , 2017, 16, 750-755.	2.5	51
113	Clinical and epidemiological aspects in the antiphospholipid syndrome. <i>Immunobiology</i> , 2003, 207, 5-11.	0.8	50
114	Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 154-158.	0.6	50
115	Systemic lupus erythematosus and hypertension. <i>Autoimmunity Reviews</i> , 2019, 18, 102371.	2.5	50
116	Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. <i>Immunologic Research</i> , 2013, 56, 358-361.	1.3	48
117	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	2.3	48
118	Catastrophic APS in the Context of Other Thrombotic Microangiopathies. <i>Current Rheumatology Reports</i> , 2015, 17, 482.	2.1	46
119	Catastrophic antiphospholipid syndrome: task force report summary. <i>Lupus</i> , 2014, 23, 1283-1285.	0.8	45
120	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
121	Catastrophic antiphospholipid syndrome and sepsis. A common link?. <i>Journal of Rheumatology</i> , 2007, 34, 923-6.	1.0	45
122	Catastrophic Antiphospholipid Syndrome: Treatment, Prognosis, and the Risk of Relapse. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 80-84.	2.9	44
123	Vitamin D and Sjögren syndrome. <i>Autoimmunity Reviews</i> , 2017, 16, 587-593.	2.5	44
124	Coronary and valvular syndromes and antiphospholipid antibodies. <i>Thrombosis Research</i> , 2004, 114, 501-507.	0.8	43
125	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1924-1930.	0.4	43
126	<i>Toxoplasma gondii</i> : bystander or cofactor in rheumatoid arthritis. <i>Immunologic Research</i> , 2013, 56, 287-292.	1.3	43

#	ARTICLE	IF	CITATIONS
127	Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics. <i>Immunobiology</i> , 2005, 210, 735-741.	0.8	42
128	Antiphospholipid syndrome dilemmas still to be solved: 2008 status: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 438-442.	0.5	41
129	Lessons from the "Euro-Phospholipid" project. <i>Autoimmunity Reviews</i> , 2008, 7, 174-178.	2.5	39
130	Catastrophic antiphospholipid syndrome: The current management approach. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 239-249.	1.4	39
131	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	1.5	39
132	Is there a microangiopathic antiphospholipid syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 429-432.	0.5	38
133	Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. <i>Autoimmunity Reviews</i> , 2015, 14, 586-593.	2.5	38
134	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	1.8	38
135	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	2.5	38
136	Amputation of Digits or Limbs in Patients with Antiphospholipid Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 124-131.	1.6	37
137	"Non-criteria" antiphospholipid syndrome: A nomenclature proposal. <i>Autoimmunity Reviews</i> , 2020, 19, 102689.	2.5	37
138	Relapsing Catastrophic Antiphospholipid Syndrome Potential Role of Microangiopathic Hemolytic Anemia in Disease Relapses. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 417-423.	1.6	34
139	Catastrophic antiphospholipid syndrome: an update. <i>Panminerva Medica</i> , 2017, 59, 254-268.	0.2	34
140	Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the "CAPS Registry". <i>Autoimmunity Reviews</i> , 2022, 21, 103055.	2.5	34
141	Solid cancer, antiphospholipid antibodies, and venous thromboembolism†. <i>Autoimmunity Reviews</i> , 2011, 10, 222-227.	2.5	33
142	Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2013, 12, 607-616.	2.5	32
143	The role of infectious diseases in the catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 1066-1071.	2.5	31
144	Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. <i>Autoimmunity Reviews</i> , 2006, 6, 81-84.	2.5	30

#	ARTICLE	IF	CITATIONS
145	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp>: Assessment by Drug Levels and Self-administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 374-382.	2.3	30
146	Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2009, 28, 65-70.	1.0	29
147	Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1582-1592.	0.9	29
148	Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2006, 6, 68-71.	2.5	28
149	Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: A systematic review and meta-regression. <i>PLoS ONE</i> , 2018, 13, e0196113.	1.1	28
150	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1820-1826.	1.5	28
151	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	0.8	28
152	Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2019, 41, 1839-1862.	1.1	27
153	Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2020, 297, 55-63.	0.4	27
154	Susac's syndrome: An update. <i>Autoimmunity Reviews</i> , 2011, 10, 548-552.	2.5	26
155	Coste económico directo del control y el tratamiento del lupus eritematoso sistémico activo y sus brotes en España: estudio LUCIE. <i>Revista Clinica Espanola</i> , 2013, 213, 127-137.	0.2	26
156	Catastrophic Antiphospholipid Syndrome. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 391-400.	0.7	26
157	16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1594-1600.	0.8	26
158	Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1218-1226.	0.5	26
159	Catastrophic Antiphospholipid Syndrome: Lessons from the "CAPS Registry" A Tribute to the Late Josep Font. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 448-456.	1.8	25
160	Catastrophic Antiphospholipid Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 575-590.	0.8	24
161	Antiphospholipid syndrome. <i>Arthritis Research and Therapy</i> , 2008, 10, 230.	1.6	24
162	Autoimmunity and Recurrent Pregnancy Losses. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 39, 148-152.	2.9	23

#	ARTICLE	IF	CITATIONS
163	Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2012, 11, 705-712.	2.5	23
164	Recurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 265-274.	2.9	23
165	Renal Involvement in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2014, 16, 397.	2.1	23
166	Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 184-191.	2.5	23
167	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
168	The epidemiology and significance of autoimmune diseases in health care. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2001, 61, 27-30.	0.6	21
169	Do we still need renal biopsy in lupus nephritis?. <i>Reumatologia</i> , 2016, 54, 61-66.	0.5	21
170	Repeated Renal Biopsy - A Predictive Tool to Assess the Probability of Renal Flare in Lupus Nephritis. <i>American Journal of Nephrology</i> , 2016, 44, 439-446.	1.4	21
171	Effects of Î²2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. <i>Arthritis and Rheumatism</i> , 2002, 46, 3283-3289.	6.7	20
172	European Working Party on Systemic Lupus Erythematosus: A 15-year report. <i>Autoimmunity Reviews</i> , 2006, 5, 549-553.	2.5	20
173	Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2006, 6, 85-88.	2.5	20
174	Peripheral Vascular Occlusions Leading to Gangrene and Amputations in Antiphospholipid Antibody Positive Patients. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 515-529.	1.8	20
175	Rituximab and its therapeutic potential in catastrophic antiphospholipid syndrome. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 26-30.	1.2	20
176	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). <i>RMD Open</i> , 2020, 6, e001192.	1.8	20
177	Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. <i>Journal of Clinical Rheumatology</i> , 2002, 8, 157-65.	0.5	20
178	Basophils, IgE, and Autoantibody-Mediated Kidney Disease. <i>Journal of Immunology</i> , 2011, 186, 6083-6090.	0.4	19
179	Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 1895-1896.	1.0	19
180	Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	19

#	ARTICLE	IF	CITATIONS
181	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	1.0	19
182	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
183	Treat-to-target in systemic lupus erythematosus: Where are we?. <i>European Journal of Internal Medicine</i> , 2020, 74, 29-34.	1.0	19
184	Automated Detection of Lupus White Matter Lesions in MRI. <i>Frontiers in Neuroinformatics</i> , 2016, 10, 33.	1.3	18
185	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021, 10, 783.	1.0	18
186	The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. <i>Journal of Nephrology</i> , 2021, 34, 1897-1905.	0.9	18
187	The catastrophic antiphospholipid syndrome--Asherson's syndrome. <i>Annales De Médecine Interne</i> , 2003, 154, 195-6.	0.2	18
188	Novelties in the field of autoimmunity " 1st Saint Petersburg congress of autoimmunity, the bridge between east and west. <i>Autoimmunity Reviews</i> , 2017, 16, 1175-1184.	2.5	17
189	The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 929-935.	0.4	17
190	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	2.2	17
191	Morbidity and mortality in the antiphospholipid syndrome. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 413-417.	1.2	15
192	Lack of association between serum 25-hydroxyvitamin D levels and cervical human papillomavirus infection in systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 606-612.	0.8	15
193	Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. <i>Lupus</i> , 2020, 29, 1050-1059.	0.8	15
194	Beta-2-Microglobulin Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019. <i>ACR Open Rheumatology</i> , 2021, 3, 267-276.	0.9	15
195	Antiphospholipid Syndrome.. <i>Journal of Investigative Dermatology</i> , 1993, 100, 21S-27S.	0.3	14
196	Magnetic Resonance Imaging in Neuropsychiatric Lupus. <i>F1000Research</i> , 2015, 4, 162.	0.8	14
197	The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty?. <i>Autoimmunity Reviews</i> , 2017, 16, 1119-1124.	2.5	13
198	The H1 haplotype of the endothelial protein C receptor protects against arterial thrombosis in patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , 2018, 169, 128-134.	0.8	13

#	ARTICLE	IF	CITATIONS
199	The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. <i>Clinical Rheumatology</i> , 2021, 40, 2057-2063.	1.0	13
200	Advanced and Conventional Magnetic Resonance Imaging in Neuropsychiatric Lupus. <i>F1000Research</i> , 2015, 4, 162.	0.8	13
201	Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk. <i>Frontiers in Immunology</i> , 2021, 12, 754469.	2.2	13
202	Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 926-32.	0.4	13
203	Venous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind. <i>Autoimmunity Reviews</i> , 2012, 12, 289-294.	2.5	12
204	Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. <i>Antibodies</i> , 2016, 5, 18.	1.2	12
205	Plasma exchange in catastrophic antiphospholipid syndrome. <i>Presse Medicale</i> , 2019, 48, 347-353.	0.8	12
206	Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 102406.	2.5	11
207	IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. <i>Scientific Reports</i> , 2020, 10, 11010.	1.6	11
208	Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders. <i>Autoimmunity Reviews</i> , 2022, 21, 103014.	2.5	11
209	Incidence of Vertebral Fractures in Women with Systemic Lupus Erythematosus After 8 Years of Follow-Up. <i>Calcified Tissue International</i> , 2017, 101, 291-299.	1.5	10
210	Systemic lupus erythematosus, endothelial progenitor cells and intracellular Ca <sup>2+</sup> signaling: A novel approach for an old disease. <i>Journal of Autoimmunity</i> , 2020, 112, 102486.	3.0	10
211	Catastrophic Antiphospholipid Syndrome - 20 Years Later. <i>Current Rheumatology Reviews</i> , 2013, 9, 73-80.	0.4	10
212	Lessons from the "Euro-Lupus Cohort". <i>Annales De Médecine Interne</i> , 2002, 153, 530-6.	0.2	10
213	Multiorgan failure due to rapid occlusive vascular disease in antiphospholipid syndrome: the 'catastrophic' antiphospholipid syndrome. <i>APLAR Journal of Rheumatology</i> , 2004, 7, 254-262.	0.2	9
214	Procoagulant microparticles are increased in patients with Behçet's disease but do not define a specific subset of clinical manifestations. <i>Clinical Rheumatology</i> , 2016, 35, 695-699.	1.0	9
215	Association between allelic variants of the human glucocorticoid receptor gene and autoimmune diseases: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2018, 17, 449-456.	2.5	9
216	Rheumatoid arthritis in the indigenous qom population of Rosario, Argentina: aggressive and disabling disease with inadequate adherence to treatment in a community-based cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 2323-2330.	1.0	9

#	ARTICLE	IF	CITATIONS
217	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	1.9	9
218	Autoantibodies, elevated cytokines, and neurocognitive abnormalities in offspring of women with systemic lupus erythematosus: comparison with healthy controls. <i>Clinical Rheumatology</i> , 2019, 38, 2529-2539.	1.0	9
219	Economic Analysis of the Use of Anti-DFS70 Antibody Test in Patients with Undifferentiated Systemic Autoimmune Disease Symptoms. <i>Journal of Rheumatology</i> , 2020, 47, 1275-1284.	1.0	9
220	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€Registryâ€™™). <i>Lupus Science and Medicine</i> , 2022, 9, e000633.	1.1	9
221	ORIGINAL ARTICLE: Thrombin Activatable Fibrinolysis Inhibitor and Clot Lysis Time in Pregnant Patients with Antiphospholipid Syndrome: Relationship with Pregnancy Outcome and Thrombosis. <i>American Journal of Reproductive Immunology</i> , 2009, 62, 381-389.	1.2	8
222	Anti-GalNAc $\beta$ : A novel anti-glycan autoantibody associated with pregnancy loss in women with antiphospholipid syndrome and in a mouse experimental model. <i>Journal of Autoimmunity</i> , 2012, 39, 420-427.	3.0	8
223	Facts and challenges for the autoimmunologist. Lessons from the second Colombian autoimmune symposium. <i>Autoimmunity Reviews</i> , 2012, 11, 249-251.	2.5	8
224	Systemic Lupus Erythematosus 2014. <i>Autoimmune Diseases</i> , 2014, 2014, 1-2.	2.7	8
225	Genital <i>Mycoplasma</i> infection among Mexican women with systemic lupus erythematosus. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 17-22.	1.0	8
226	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368.	0.8	8
227	The impact of antimalarial agents on traditional and non-traditional subclinical atherosclerosis biomarkers in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102887.	2.5	8
228	Classification criteria for SLE: the latestâ€™but not leastâ€™ attempt. <i>Nature Reviews Rheumatology</i> , 2012, 8, 506-507.	3.5	7
229	Carotid atherosclerosis is not associated with lower bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 25-31.	0.8	7
230	The problems and pitfalls in systemic lupus erythematosus drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 525-527.	2.5	7
231	Factors Associated with Mortality in Patients with Autoimmune Diseases Admitted to the Intensive Care Unit in Bogota, Colombia. <i>Frontiers in Immunology</i> , 2017, 8, 337.	2.2	7
232	Discordance between patient and physician global assessment of disease activity in Behçetâ€™™s syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 278.	1.6	7
233	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. <i>Rheumatology</i> , 2020, 59, 3690-3699.	0.9	7
234	Management of Reproductive Failure in the Antiphospholipid Syndrome. , 2002, , 375-394.		7

#	ARTICLE	IF	CITATIONS
235	Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature. <i>Brain Sciences</i> , 2021, 11, 1641.	1.1	7
236	Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4946.	1.8	7
237	Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
238	Management of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2010, 1, 15-22.	3.9	6
239	FRIO193â€¦2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
240	The epidemiology of systemic lupus erythematosus: a review of the current data with special emphasis on the lessons from the â€Euro-lupus Cohortâ€™™. <i>APLAR Journal of Rheumatology</i> , 2003, 6, 150-157.	0.2	5
241	Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. <i>Lupus</i> , 2021, 30, 134-140.	0.8	5
242	Future Perspectives in the Diagnosis of Neuropsychiatric Lupus by Advanced Magnetic Resonance Imaging Techniques. <i>Current Rheumatology Reviews</i> , 2018, 14, 213-218.	0.4	5
243	Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2081-2088.	1.4	5
244	Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus. <i>Clinical Investigation</i> , 2015, 5, 561-571.	0.0	4
245	Systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 289-290.	1.4	4
246	Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines. <i>Expert Review of Hematology</i> , 2021, 14, 457-466.	1.0	4
247	Catastrophic antiphospholipid syndrome. <i>Revista Colombiana De ReumatologÃa</i> , 2021, 28, 39-43.	0.0	4
248	The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study. <i>Arthritis Research and Therapy</i> , 2022, 24, 9.	1.6	4
249	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. <i>European Journal of Internal Medicine</i> , 2022, 99, 19-21.	1.0	4
250	Asymptomatic coronary artery disease assessed by coronary computed tomography in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2022, 100, 102-109.	1.0	4
251	The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the â€œCatastrophic antiphospholipid syndrome registryâ€™. <i>Lupus</i> , 2022, 31, 1218-1225.	0.8	4
252	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 2022, 31, 1344-1354.	0.8	4

#	ARTICLE	IF	CITATIONS
253	Cardiac manifestations of the antiphospholipid syndrome. <i>Coronary Artery Disease</i> , 1993, 4, 1137-1144.	0.3	3
254	Catastrophic antiphospholipid (Asherson's) syndrome. <i>British Journal of Hospital Medicine (London)</i> , 2017, 10, 10-11.	0.2	3
255	Current management of catastrophic antiphospholipid syndrome. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 297-303.	0.3	3
256	Prolonged Remission in SLE Revisited: An Old Wine in a New Bottle. <i>Journal of Rheumatology</i> , 2014, 41, 1728-1731.	1.0	3
257	History, Classification, and Subsets of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 1-16.	0.1	3
258	Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. <i>Rheumatology</i> , 2018, 57, .	0.9	3
259	Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S67-71.	0.4	3
260	Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center. <i>Arthritis Research and Therapy</i> , 2022, 24, 91.	1.6	3
261	Thromboembolism risk following recurrent miscarriage. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1503-1513.	0.6	2
262	Repeat renal biopsy in lupus nephritis – unnecessary harm and risk of complications or important diagnostic tool with clinical consequences?. <i>Reumatologia</i> , 2016, 54, 49-50.	0.5	2
263	ABO165...THE EUROPEAN REGISTRY ON OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (EUROAPS): A SURVEY OF 1100 CONSECUTIVE CASES. , 2019, , .		2
264	Targeting interferon I in SLE: a promising new perspective. <i>Lancet Rheumatology</i> , The, 2020, 2, e581-e582.	2.2	2
265	Precision medicine and the antiphospholipid syndrome: what is the future?. <i>Clinical Rheumatology</i> , 2020, 39, 1015-1017.	1.0	2
266	Causes of Hospitalization in Systemic Lupus Erythematosus: A Narrative Review. <i>Current Rheumatology Reviews</i> , 2021, 17, 29-40.	0.4	2
267	Antimalarial-induced retinal toxicity. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 132-143.	0.0	2
268	Prolactin and Estradiol Profile in a Cohort of Colombian Women with Systemic Lupus Erythematosus. <i>Israel Medical Association Journal</i> , 2016, 18, 537-541.	0.1	2
269	Deletions in VANGL1 are a risk factor for antibody-mediated kidney disease. <i>Cell Reports Medicine</i> , 2021, 2, 100475.	3.3	2
270	Ronald A. Asherson – In Memoriam. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 71-73.	2.9	1

#	ARTICLE	IF	CITATIONS
271	Systemic Lupus Erythematosus. <i>Autoimmune Diseases</i> , 2012, 2012, 1-2.	2.7	1
272	The anti-phospholipid syndrome: 30 years in the forefront (1983-2013). <i>Rheumatology</i> , 2013, 52, 1347-1348.	0.9	1
273	Diagnosing catastrophic antiphospholipid syndrome: the necessity for clinical awareness. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 1-3.	0.3	1
274	Treatment of Catastrophic Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 243-255.	0.1	1
275	Thrombotic Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 87-106.	0.1	1
276	Overrepresentation of Elderly Subjects in a Population-Based Study of Antiphospholipid Syndrome: Comment on the Article by Duarte-García et al. <i>Arthritis and Rheumatology</i> , 2019, 71, 1768-1769.	2.9	1
277	Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 30-41.	1.0	1
278	O31...Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
279	Editorial: Primary Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 1993.	2.2	1
280	Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021, 60, e181-e183.	0.9	1
281	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	1.1	1
282	Non-criteria Manifestations of Antiphospholipid Syndrome: An Overview. <i>Spanish Journal of Medicine</i> , 2021, 1, .	0.0	1
283	Treat to target in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 101-106.	0.0	1
284	Understanding tubulointerstitial injury and repair mechanisms paves the way for renal outcome improvement in lupus nephritis. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 82-89.	0.0	1
285	COVID-19 coagulopathy and antiphospholipid syndrome. <i>Revista Colombiana De Reumatología</i> , 2022, 29, S25-S34.	0.0	1
286	15th International Congress on Antiphospholipid Antibodies Task Force on Catastrophic Antiphospholipid Syndrome Report. , 2017, , 307-316.		1
287	Catastrophic antiphospholipid syndrome: therapeutic developments. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 277-285.	1.3	0
288	Treatment of Antiphospholipid Syndrome. , 2011, , 1027-1042.		0

#	ARTICLE	IF	CITATIONS
289	Therapeutic Perspectives in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2011, 7, 313-321.	0.4	0
290	Immunotherapeutic Agents for SLE. , 2012, , .		0
291	Editorial paper Catastrophic antiphospholipid syndrome: 20 years of research work (1992â€“2012). <i>Reumatología</i> , 2012, 5, 363-369.	0.5	0
292	Developing an appropriately supported CME-accredited programme in Europe. <i>Journal of European CME</i> , 2013, 2, 37-44.	0.6	0
293	Pathogenic Mechanisms and Clinical Relevance of Autoantibodies. , 2014, , 51-57.		0
294	Reply. <i>Arthritis and Rheumatology</i> , 2014, 66, 480-480.	2.9	0
295	The Infectious Origin of the Anti-Phospholipid Syndrome. , 2015, , 681-696.		0
296	¿Sigue siendo necesaria la biopsia renal en la nefropatía lúpica?. <i>Revista Colombiana De Reumatología</i> , 2016, 23, 69-72.	0.0	0
297	Is the renal biopsy still necessary in lupus nephropathy?. <i>Revista Colombiana De Reumatología (English)</i> Tj ETQq1 1 0.784314 rgBT /O	0.1	0
298	La investigación sobre tratamientos biológicos en el lupus eritematoso sistémico. <i>Medicina Clínica</i> , 2017, 148, 67-68.	0.3	0
299	Prognosis in Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 281-294.	0.1	0
300	Research on biological therapies in systemic lupus erythematosus. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 67-68.	0.1	0
301	05.06â€¦Specific t cell and b cell distributions characterise subgroups of patients with primary Sjögren's syndrome and are associated with disease activity and pro-inflammatory cytokine expression. , 2017, , .		0
302	Catastrophic Antiphospholipid Syndrome. , 2019, , 493-500.		0
303	Reply to the editor. <i>Autoimmunity Reviews</i> , 2019, 18, 435-436.	2.5	0
304	FRI0192â€¦A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
305	03â€¦Family planning and SLE: from conception through child-bearing. , 2019, , .		0
306	26â€¦Refractory and/or catastrophic APS in SLE. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
307	06â€¦Microangiopathy in SLE: a diagnostic and therapeutic challenge. , 2020, , .		0
308	Le Relapsing Polychondritis Damage Index (RPDAM)Â: dÃ©veloppement dâ€™un score lâ€™sionnel au cours de la polychondrite atrophiante. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 122-127.	0.0	0
309	Catastrophic antiphospholipid syndrome presenting with aortic barrage: case report and review of the literature. Lupus, 2021, 30, 1005-1009.	0.8	0
310	The antiphospholipid syndrome. Revista Colombiana De ReumatologÃa, 2021, 28, 166-176.	0.0	0
311	Anti Ro52 antibodies: One step further, but still not there yet. European Journal of Internal Medicine, 2021, 91, 31-32.	1.0	0
312	Relationship between serum lipopolysaccharide binding protein levels, disease activity, and clinical characteristics in Paraguayan patients with systemic lupus erythematosus. Lupus, 2021, 30, 096120332110503.	0.8	0
313	Task Force Report on Catastrophic Antiphospholipid Syndrome. , 2012, , 181-193.		0
314	Task Force Report on Non-criteria Manifestations: Cardiac Valve Disease. , 2012, , 223-233.		0
315	Heart Valve Lesions In The Antiphospholipid Syndrome. Current Rheumatology Reviews, 2012, 8, 161-165.	0.4	0
316	Cost-effectiveness analysis of treatments for the first episode of catastrophic antiphospholipid syndrome: A study based on the catastrophic antiphospholipid syndrome registry. Lupus, 2022, 31, 194-201.	0.8	0
317	Los criterios del lupus eritematoso sistÃ©mico en la actualidad. Medicina ClÃnica, 2022, , .	0.3	0
318	Patients with laboratory criteria of anti-phospholipid syndrome and â€œnon-criteriaâ€™ manifestations: a multicenter cohort. Scandinavian Journal of Rheumatology, 0, , 1-6.	0.6	0